BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krishnamurthy S, Lockey RF, Kolliputi N. Soluble ACE2 as a potential therapy for COVID-19. Am J Physiol Cell Physiol 2021;320:C279-81. [PMID: 33502950 DOI: 10.1152/ajpcell.00478.2020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Nazerian Y, Vakili K, Ebrahimi A, Niknejad H. Developing Cytokine Storm-Sensitive Therapeutic Strategy in COVID-19 Using 8P9R Chimeric Peptide and Soluble ACE2. Front Cell Dev Biol 2021;9:717587. [PMID: 34540833 DOI: 10.3389/fcell.2021.717587] [Reference Citation Analysis]
2 Singh B, Singh D, Verma V, Yadav R, Kumar R. Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review. J Pharm Anal 2021. [PMID: 34934510 DOI: 10.1016/j.jpha.2021.12.003] [Reference Citation Analysis]
3 de la Fuente M, Lombardero L, Gómez-González A, Solari C, Angulo-Barturen I, Acera A, Vecino E, Astigarraga E, Barreda-Gómez G. Enzyme Therapy: Current Challenges and Future Perspectives. Int J Mol Sci 2021;22:9181. [PMID: 34502086 DOI: 10.3390/ijms22179181] [Reference Citation Analysis]
4 Verma HK, Bhaskar L. SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted. World J Gastroenterol 2021; 27(45): 7855-7858 [PMID: 34963747 DOI: 10.3748/wjg.v27.i45.7855] [Reference Citation Analysis]
5 Wu C, Xu Q, Wang H, Tu B, Zeng J, Zhao P, Shi M, Qiu H, Huang Y. Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles. Acta Pharm Sin B 2021. [PMID: 34522576 DOI: 10.1016/j.apsb.2021.09.004] [Reference Citation Analysis]
6 Gallo CG, Fiorino S, Posabella G, Antonacci D, Tropeano A, Pausini E, Pausini C, Guarniero T, Hong W, Giampieri E, Corazza I, Federico L, de Biase D, Zippi M, Zancanaro M. COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us? Cytokine 2021;148:155628. [PMID: 34411989 DOI: 10.1016/j.cyto.2021.155628] [Reference Citation Analysis]
7 Angeli F, Zappa M, Reboldi G, Trapasso M, Cavallini C, Spanevello A, Verdecchia P. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. Eur J Intern Med 2021;93:28-34. [PMID: 34588140 DOI: 10.1016/j.ejim.2021.09.007] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Angus-Leppan H, Guiloff AE, Benson K, Guiloff RJ. Navigating migraine care through the COVID-19 pandemic: an update. J Neurol 2021. [PMID: 34002281 DOI: 10.1007/s00415-021-10610-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Díaz-troyano N, Gabriel-medina P, Weber S, Klammer M, Barquín-delpino R, Castillo-ribelles L, Esteban A, Hernández-gonzález M, Ferrer-costa R, Pumarola T, Rodríguez-frías F. Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2. Diagnostics 2022;12:886. [DOI: 10.3390/diagnostics12040886] [Reference Citation Analysis]
10 Vassiliou AG, Zacharis A, Keskinidou C, Jahaj E, Pratikaki M, Gallos P, Dimopoulou I, Kotanidou A, Orfanos SE. Soluble Angiotensin Converting Enzyme 2 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in COVID-19-induced Acute Respiratory Distress Syndrome (ARDS). Pharmaceuticals (Basel) 2021;14:695. [PMID: 34358119 DOI: 10.3390/ph14070695] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Gupta D, Kumar A, Mandloi A, Shenoy V. Renin angiotensin aldosterone system in pulmonary fibrosis: Pathogenesis to therapeutic possibilities. Pharmacol Res 2021;174:105924. [PMID: 34607005 DOI: 10.1016/j.phrs.2021.105924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hagiu BA. Moderate exercise may prevent the development of severe forms of COVID-19, whereas high-intensity exercise may result in the opposite. Med Hypotheses 2021;157:110705. [PMID: 34670172 DOI: 10.1016/j.mehy.2021.110705] [Reference Citation Analysis]